A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)

[Background] Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose...

ver descrição completa

Detalhes bibliográficos
Autores: Machiels, Jean-Pascal, Salazar, Ramón, Rottey, Sylvie, Durán, Ignacio, Dirix, Luc, Geboes, Karen, Wilkinson-Blanc, Christine, Pover, Gillian, Alvis, Simon, Champion, Brian, Fisher, Kerry, McElwaine-Johnn, Hilary, Beadle, John, Calvo, Emiliano
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/203801
Acesso em linha:http://hdl.handle.net/10261/203801
Access Level:acceso abierto
Palavra-chave:Clinical trials
Pharmacokinetics and pharmacodynamics
Enadenotucirev
Oncolytic adenovirus
Epithelialsolid tumor
Intravenous
Descrição
Resumo:[Background] Enadenotucirev is a chimeric adenovirus with demonstrated preclinical tumor-selective cytotoxicity and a short half-life. Further clinical mechanism of action data showed that enadenotucirev can gain access to and replicate within different types of epithelial tumors. This phase 1 dose escalation study assessed intravenous (IV) dose escalation with enadenotucirev to establish the maximum tolerated dose (MTD) and subsequently identify a suitable schedule for repeated cycles.

Registos relacionados